Evaluation of the Safety and Efficacy of an Injectable Liposomal Gel

Exclusion Criteria

• •1. Scars, birthmarks, or tattoos on the face that could interfere with the assessment of skin condition;
• •2. Presence of open wounds, ulcers, active infections, or other significant skin damage at the planned injection site;
• •3. Receipt of intradermal facial injections with native hyaluronic acid, platelet-rich plasma, or other injectable therapies within 6 months prior to study initiation;
• •4. Receipt of intradermal facial injections with slowly absorbable or non-absorbable filler products within 12 months prior to study initiation;
• •5. Known hypersensitivity to any component of the investigational product;
• •6. Dermatitis or dermatological disease of inflammatory and/or infectious nature at the planned injection site;
• •7. History of cancer, autoimmune disease, or immunodeficiency;
• •8. Use of medications affecting blood coagulation;
• •9. Use of topical antihistamines, corticosteroids, or retinoids on the face within 4 weeks prior to the study;
• •10. Pregnancy or breastfeeding;
• •11. Participation or planned participation in other clinical trials;